BNBX
BNB PLUS CORP.
+0.02 (+14.29%)0.16USD6.4K成交股數992K市值0.0本益比(近四季)0.4股價營收比+98.9%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 9 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 605K+99% | 1.0M+34% | 565K-35% | 199K-58% | 304K-67% | 763K-14% | 870K+12% | 473K-84% | 930K | 891K | 780K | 2.9M |
| 營業成本 | 158K | 197K | 250K | 367K | 299K | 367K | 264K | 230K | 634K | 660K | 701K | 1.6M |
| 毛利 | 447K+8616% | 827K+109% | 315K-48% | −168K-169% | 5K-98% | 396K+71% | 606K+667% | 243K-81% | 296K | 231K | 79K | 1.3M |
| 毛利率 | 73.9% | 80.7% | 55.8% | -84.2% | 1.7% | 51.8% | 69.7% | 51.3% | 31.8% | 25.9% | 10.1% | 43.5% |
| 研發費用 | 210K | 372K | 459K | 3.4M | 769K | 849K | 1.0M | 913K | 913K | 936K | 939K | 836K |
| 銷售管理費用 | 2.1M | 2.6M | 13.3M | 2.4M | 2.9M | 2.9M | 2.6M | 2.6M | 3.0M | 3.1M | 3.3M | 3.3M |
| 營業利益 | −3.2M-12% | −6.8M+100% | −18.7M+528% | −6.0M+81% | −3.7M+2% | −3.4M-11% | −3.0M-29% | −3.3M+16% | −3.6M | −3.8M | −4.2M | −2.9M |
| 營業利益率 | -535.4% | -659.2% | -3,308.9% | -3,007.1% | -1,213.6% | -442.8% | -342.2% | -699.3% | -389.2% | -425.2% | -534.9% | -98.0% |
| 稅後淨利 | −4.7M+19% | −6.7M+102% | −18.6M+604% | −5.3M-380% | −3.9M-12% | −3.3M+199% | −2.6M-27% | 1.9M-161% | −4.5M | −1.1M | −3.6M | −3.1M |
| 淨利率 | -774.2% | -650.8% | -3,288.6% | -2,643.4% | -1,296.1% | -433.2% | -303.3% | 397.6% | -480.9% | -124.0% | -460.7% | -106.3% |
| 稀釋 EPS | -0.57-98% | -0.68-100% | -2.08-100% | 547.60-53% | -34.00-87% | -230.30+13212% | -417.53+3689% | 1170.48-24485% | -265.45 | -1.73 | -11.02 | -4.80 |
| 稀釋股數 | 8.4M | 9.7M | 8.9M | 518K | 572K | 118K | 42.0K | 1.6K | 17.4K | 684K | 654K | 645K |
資產負債表 期末餘額
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 3.8M | 949K | 2.5M | 1.7M | 4.7M | 6.8M | 9.3M | 10.4M | 3.1M | 3.4M | 7.2M | 10.8M |
| 應收帳款 | 45K | 303K | 547K | 237K | 199K | 690K | 912K | 514K | 409K | 451K | 256K | 683K |
| 存貨 | 27K | 115K | 90K | 84K | 339K | 349K | 469K | 470K | 336K | 377K | 330K | 276K |
| 總資產 | 15.0M | 13.6M | 20.7M | 4.4M | 9.9M | 13.0M | 16.0M | 16.7M | 9.2M | 9.9M | 13.7M | 15.8M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 2.0M | 1.5M | 2.2M | 2.5M | 2.9M | 2.8M | 3.4M | 4.5M | 9.4M | 5.8M | 8.8M | 8.6M |
| 股東權益 | 9.5M | 12.5M | 18.8M | 2.3M | 7.3M | 10.5M | 12.8M | 12.4M | −48K | 4.2M | 5.0M | 7.2M |
| 負債比 | 13.6% | 11.0% | 10.8% | 56.2% | 29.7% | 21.6% | 21.4% | 26.7% | 101.9% | 58.4% | 64.3% | 54.4% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | – | −5.5M+67% | – | – | – | −3.3M | – | – | −3.8M | – | – |
| 資本支出 | – | – | – | – | – | – | 117K | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | −3.4M | – | – | – | – | – |
| 折舊攤銷 | – | – | 49K | – | – | – | 35K | – | – | 299K | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | -395.6% | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 2.1M
| Dna Tagging And Security Products | 1.1M | 53.8% | -5.7% |
|---|---|---|---|
| Therapeutic Dna Production | 988K | 46.2% | +10.4% |
地區2025 年度 · 2.1M
| Asia And Other | 1.0M | 47.8% | +3.2% |
|---|---|---|---|
| 美洲 | 1.0M | 47.3% | +6.2% |
| 歐洲 | 106K | 4.9% | -38.7% |
產品／服務2025 年度 · 4.3M
| 產品 | 1.4M | 33.3% | +32.5% |
|---|---|---|---|
| Supply Chain | 1.1M | 26.9% | -5.0% |
| 服務 | 713K | 16.7% | -31.4% |
| Large Scale Dna Production | 612K | 14.3% | +4.8% |
| Research And Development Services | 376K | 8.8% | +20.7% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 2.1M | +1.1% | −15.2M | -709.5% | -134.23 | −12.6M |
| FY2024 | 2.1M | -84.2% | −7.0M | -330.9% | -1366.42 | −14.1M |
| FY2023 | 13.4M | -26.4% | −9.9M | -74.4% | -15.21 | −6.3M |
| FY2022 | 18.2M | +101.3% | −8.3M | -45.5% | -0.93 | −9.5M |
| FY2021 | 9.0M | +367.4% | −14.3M | -158.3% | -2.07 | −15.9M |
| FY2020 | 1.9M | -64.2% | −13.0M | -674.5% | -3.32 | −12.2M |
| FY2019 | 5.4M | +38.1% | −8.6M | -160.0% | -9.69 | −6.9M |
| FY2018 | 3.9M | – | −11.7M | -299.6% | -15.86 | −7.2M |